New 'Living Drug' trial targets tough blood cancers
NCT ID NCT07347418
Summary
This is a first-in-human study testing a new type of CAR T-cell therapy for adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. Doctors will collect a patient's own immune cells, genetically modify them to target a protein called CD64 on cancer cells, and infuse them back. The main goal is to find the safest dose and see how well the modified cells survive and expand in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.